Browsing tag:

Amphotericin B


Amphotericin B

Amphotericin B: CAS No: 1397-89-3 Amphotericin B is an API used to treat a number of fungal infections. This pharmaceutical ingredient is aggressive when interacting with the fungus which is why it’s generally used for serious cases only. However, it’s also proven itself to be one of the most effective ways to stop the spread[…]

Read More

Anidulafungin

Anidulafungin CAS No: 166663-25-8 Anidulafungin is an antifungal API used to combat general yeast infections found in the blood, stomach, or esophagus and some varieties of Aspergillus. As an echinocandin, it inhibits the growth of fungal cell walls which results in either fungal cell instability or death. Echinocandins are unique in that they affect the[…]

Read More

Posaconazole

Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]

Read More

Amphotericin B is also known as the brand name Ambisone. With Astellas Pharma’s patent for Ambisome due to expire on February 23, 2016, this injectable medication for deadly fungal infections is geared up for attention in the pharmaceutical community. More than 6 billion dollars is spent worldwide on anti-fungal medications, and the total costs of[…]

Read More

Voriconazole is also known as the brand name Vfend, which is marketed by Pfizer. As an antifungal medication, voriconazole is typically reserved for treating patients with serious fungal infections, like invasive aspergillosis. Voriconazole is a formidable opponent for fungal infections that begin in the lungs and spread through the bloodstream to other organs, like invasive[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service